Company Overview
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -91.42% |
| 6 Months: | +37.85% |
| 3 Months: | +47.50% |
| 1 Month: | -2.32% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)48.27 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 96.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | QNCX Quince Therapeutics, Inc. PHARMA | 29.50 | -0.14 | $30.00M | 0.00% | -100.26% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 12.93M | 9.89M | 11.36M | 16.24M | 11.11M |
| Operating Income | -2.76M | -2.64M | -2.87M | -6.08M | -9.57M | -10.57M | -17.86M | -18.27M | -21.91M | -23.31M | -21.78M | -21.68M | -21.86M | -16.26M | -7.62M | -12.96M | -5.58M | -6.09M | -11.22M | -28.19M | -5.86M | -12.93M | -9.89M | -11.36M | -16.24M | -11.11M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.90M | -9.86M | -11.33M | -16.20M | -11.08M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.98M | -15.98M | -13.49M | -36.31M | 30.57M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 47.00K | 67.00K | -46.00K | 3.15M | -5.34M |
| Net Income | -3.38M | -3.11M | -2.52M | -5.68M | -9.06M | -9.86M | -17.18M | -17.61M | -21.51M | -23.09M | -21.75M | -21.71M | -21.64M | -16.56M | -7.92M | -12.25M | -4.89M | -5.35M | -11.15M | -27.73M | -5.49M | -15.03M | -16.05M | -13.44M | -39.46M | 35.91M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.74 | -0.73 | -0.72 | -0.51 | -0.22 | -0.34 | -0.14 | -0.15 | -0.26 | -0.64 | -0.13 | -68.40 | -68.00 | -50.00 | - | 57.60 |
| R&D Expense | 2.41M | 2.29M | 2.29M | 4.83M | 7.11M | 8.25M | 14.38M | 14.09M | 16.98M | 16.82M | 14.72M | 14.04M | 12.76M | 7.20M | 2.45M | 3.23M | 1.35M | 1.43M | 3.70M | 4.15M | 4.92M | 8.14M | 6.55M | 8.08M | - | 6.84M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 51.19M | 27.14M | 36.17M | 50.43M |
| Operating Income | -12.12M | -39.17M | -78.89M | -90.32M | -51.19M | -27.14M | -36.17M | -50.43M |
| EBITDA | - | - | - | - | -50.99M | -26.82M | -35.98M | -50.29M |
| Interest Expense | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -51.94M | -31.58M | -56.74M | -80.77M |
| Tax Provision | - | - | - | - | -284.00K | -197.00K | 87.00K | 3.21M |
| Net Income | -12.48M | -36.98M | -76.85M | -89.94M | -51.66M | -31.39M | -56.83M | -83.98M |
| Diluted EPS | - | - | - | -3.03 | -308.00 | -168.00 | -262.00 | -336.00 |
| R&D Expense | 10.09M | 30.21M | 61.31M | 60.80M | 25.18M | 9.45M | 18.59M | 35.38M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 72.88M | 124.37M | 189.47M | - | 103.91M | 167.90M | 114.48M | 93.52M |
| Current Assets | - | - | - | - | - | 93.75M | 77.44M | 44.04M | 22.90M |
| Cash & Equivalents | - | 24.87M | 51.21M | 133.80M | - | 44.58M | 20.75M | 6.21M | 5.81M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 1.00M | 993.00K | 882.00K | 3.62M |
| Total Liabilities | - | 1.46M | 8.89M | 17.20M | - | 3.32M | 82.82M | 84.33M | 129.24M |
| Current Liabilities | - | 1.46M | 8.89M | 17.00M | - | 3.07M | 9.57M | 7.28M | 43.23M |
| Long Term Debt | - | - | - | - | - | - | 13.43M | 14.32M | - |
| Total Debt | - | - | - | - | - | 453.00K | 13.81M | 14.81M | 18.47M |
| Total Equity | -20.28M | -32.63M | 115.48M | 172.26M | - | 100.59M | 85.08M | 30.15M | -35.71M |
| Shares Outstanding | - | - | - | - | - | 180.68K | 214.87K | 220.01K | 278.63K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.70M | -33.28M | -50.82M | - | -44.04M | -18.29M | -31.90M | -41.42M |
| Investing Cash Flow | -46.75M | -17.75M | -52.43M | - | 18.00M | -5.76M | 21.91M | 23.23M |
| Financing Cash Flow | 75.93M | 77.37M | 118.88M | - | 707.00K | 143.00K | -4.78M | 17.91M |
| Capital Expenditure | -212.00K | -55.00K | -52.00K | - | -133.00K | -160.00K | -257.00K | -352.00K |
| Free Cash Flow | -11.91M | -33.33M | -50.87M | - | -44.17M | -18.45M | -32.16M | -41.78M |
| Net Change in Cash | - | - | - | - | -25.33M | -23.91M | -14.77M | -289.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | 38.2% | -32.0% | -44.6% | - | -51.4% | -36.9% | -188.5% | 235.1% |
| ROCE % | -17.0% | -33.9% | -45.7% | - | -50.8% | -17.1% | -33.7% | -100.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Ikarian Capital, LLC | 7.39% | 72.25K | $2.13M |
| 2 | Millennium Management Llc | 7.24% | 70.78K | $2.09M |
| 3 | Balyasny Asset Management LP | 7.15% | 69.97K | $2.06M |
| 4 | Squadron Capital Management LLC | 4.13% | 40.38K | $1.19M |
| 5 | Shay Capital LLC | 1.79% | 17.47K | $514.96K |
| 6 | Boothbay Fund Management, LLC | 1.42% | 13.91K | $410.10K |
| 7 | Jane Street Group, LLC | 1.29% | 12.64K | $372.69K |
| 8 | Vanguard Capital Management LLC | 1.23% | 12.04K | $355.06K |
| 9 | Cormorant Asset Management, LP | 0.56% | 5.50K | $162.08K |
| 10 | UBS Group AG | 0.48% | 4.73K | $139.44K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QNCX
Two investor conferences will feature Quince Therapeutics in September - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOOWdnQXozbTd4Wk5iTjFBcGdRRTJiN0h3NTB0ZkhiamFRVjdGY0l5QzJXQVJvNGtEUlZFd1cwaGVLU3VwM2JKM2dkZ0lkX2tyd0tSNzBVY0ZFSm1sRGltTDRodkFhRktoSmhzYUljR1VMN3ZVTHREdXo4ZzdzeHppRDZhNkJFRFN6X1M4OE…
Quince Therapeutics Faces Nasdaq Listing Compliance Challenges - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxPaTVWOVpzT0hMdXZ2OFppV2J0QThxNGM4clV5TXdjSEJMSElKZVB0VzVZZko4a3B5c0tMSWpSN3BPbDl2WlZSQ29TT1h0NGRLTjl0MktLWVdVWWt3QXhUWmdBR1FSNklEdFlITzNXdlc5VGx5MS11TXZJcU94X29GQTFTMG5kOXpueWFpVk…
Quince Therapeutics to Participate in September 2026 Investor Conferences - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPZktZcnJFWm04b2U4XzA5bElIdlJ3RzhJeTZ2c1hGeDdUTHBNbm5scFZHci1DV1NhSVZTUFpsSW9YQllSdnU5YUFSdmo3Y2ZqZmpBOUNvN3VQcUR6Y2tfSzZ6WnlyMHBqU3dxV3YwMzc4UHVmLVE0N09sLWpjOTg1UnYzMUVWRkxQQVpDNm…
What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours - Sahm
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPOGo2Y21PRjBFcHY0QVdSZ1BQOVFyVVYwZmpublZFLXY5cU5nMmhXVVNSbmJQWlZETHhydDFQM1pJR0hNXzVIQWZYN0d0ZlB1NTh2cGJVZk1LVnhsa0EtMTk1cXp6bUlqRU04Unk5TjJubkNndk00ckRhYXJqSERldGpPbUhIby1UcnhWNW…
Why Is QNCX Stock Up 60% Pre-Market After A Near-Total Wipeout? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOazJIb0M3cWZ2YUxoQV9SVkd1aVNkU3hIV1hiY1ZWaDlQTllwS1ZSdFQycVRrZHRrU3N3dHNKY3p3RGFQcUFLbk9Kak5YVndDRWNSU3czQWhlSVJxOEFKa3ZqaVc5N1IxRmRuYjFoNFpFRTJ6NnhjZG1rd3d5aEdxSXdUamdEWHlzWURJbG…
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNOUtOSnVlWmpxTWFENldWRWF4R0FmS2ozNUx1QjgtdUZ4Nnh3dnhIRDFYZWVhalEtM0RES3dhbzFVd1VPMEZ5aENyTGgyRlloUUdBam84cWthZDBkcmZZUWZOemNMUElHMUNoLWxHU1hLYkVLbWZnM0VtUHFHeHdPblE1RmtUVmNiVFRNSG…
QNCX — Frequently Asked Questions
What is the current share price of Quince Therapeutics, Inc. (QNCX)?
As of 2026-09-19 21:16 PDT, Quince Therapeutics, Inc. (QNCX) trades at $29.50 on NasdaqGS. Its 52-week range is $16.00 to $880.00.
What is the market capitalisation of QNCX?
Quince Therapeutics, Inc. (QNCX) has a market capitalisation of $30.00M on NasdaqGS.
What is the P/E ratio of QNCX?
QNCX trades at a trailing price-to-earnings (P/E) ratio of -0.14. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.85.
Is QNCX a good stock to buy?
This page provides a data-driven analysis of Quince Therapeutics, Inc. (QNCX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.